Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Trial Profile

A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Avacincaptad pegol (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors OphthoTech Corporation
  • Most Recent Events

    • 02 Nov 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Nov 2019.
    • 04 Oct 2018 According to an OphthoTech Corporation media release, top-line data from the trial is expected during the fourth quarter of 2019.
    • 04 Oct 2018 Status changed from recruiting to active, no longer recruiting, according to an OphthoTech Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top